2026 ICD-10-CM Diagnosis Code E75.29Other sphingolipidosis

ICD-10-CM CodesE00–E89E70-E88E75

ICD-10-CM E75.29
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E75.29 is a billable ICD-10-CM diagnosis code for other sphingolipidosis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other nervous system disorders (often hereditary or degenerative) and Other specified and unspecified nutritional and metabolic disorders.

Code Identity

ICD-10-CM Code
E75.29
Billable Status
Yes — Valid for Submission
Code Describes
Other sphingolipidosis
Short Description
Other sphingolipidosis
Same as the full description in the CMS dataset.
Parent Code
Other sphingolipidosis

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE75Disorders of sphingolipid metabolism and other lipid storage disorders
This CodeE75.29Other sphingolipidosis

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • 4H leukodystrophy
  • Adult onset autosomal dominant leukodystrophy
  • Alkaline ceramidase 3 deficiency
  • C11ORF73-related autosomal recessive hypomyelinating leukodystrophy
  • Combined malformation of central nervous system and skeletal muscle
  • Deficiency of arylsulfatase
  • Deficiency of cerebroside-sulfatase
  • Deficiency of N-acetylgalactosamine-6-sulfatase
  • Deficiency of placental function
  • Deficiency of steryl-sulfatase
  • Dementia due to leukodystrophy
  • Disorder of placental endocrine function
  • Dystonia due to Pelizaeus-Merzbacher disease
  • Encephalopathy due to prosaposin deficiency
  • Galactosylceramide lipidosis
  • Hereditary cerebellar atrophy
  • Hypomyelinating leukodystrophy with atrophy of basal ganglia and cerebellum
  • Leukodystrophy
  • Metachromatic leukodystrophy
  • Metachromatic leukodystrophy due to sphingolipid activator protein I deficiency
  • Multiple sulfatase deficiency
  • Muscle eye brain disease with bilateral multicystic leukodystrophy
  • Neuroaxonal dystrophy
  • Neuroaxonal leukodystrophy
  • NKX6-2-related autosomal recessive hypomyelinating leukodystrophy
  • Non-progressive predominantly posterior cavitating leukodystrophy with peripheral neuropathy
  • Odontoleukodystrophy
  • Ovarioleukodystrophy
  • Pelizaeus Merzbacher like disease
  • Pelizaeus Merzbacher like disease due to AIMP1 mutation
  • Pelizaeus Merzbacher like disease due to GJC2 mutation
  • Pelizaeus Merzbacher like disease due to HSPD1 mutation
  • Pelizaeus Merzbacher like disease due to SLC16A2 mutation
  • Pelizaeus-Merzbacher disease
  • Pelizaeus-Merzbacher disease in female carrier
  • Pelizaeus-Merzbacher disease null syndrome
  • Pelizaeus-Merzbacher disease, classic form
  • Pelizaeus-Merzbacher disease, connatal variant
  • Peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, Hirschsprung disease
  • Placental sulfatase deficiency
  • Premature ovarian failure
  • RARS-related autosomal recessive hypomyelinating leukodystrophy
  • RNA polymerase III-related leukodystrophy
  • Spastic tetraplegia
  • Spongy degeneration of central nervous system
  • TUBB4A-related leukodystrophy
  • Type III transitional Pelizaeus-Merzbacher disease
  • Type IV adult Pelizaeus-Merzbacher disease
  • Type V atypical Pelizaeus-Merzbacher disease
  • Type VI Cockayne Pelizaeus-Merzbacher disease
  • Vanishing white matter disease
  • VPS11-related autosomal recessive hypomyelinating leukodystrophy
  • Waardenburg syndrome
  • X-linked ichthyosis with steryl-sulfatase deficiency

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Farber's syndrome
  • Sulfatide lipidosis

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Aplasia
      • axialis extracorticalis (congenita)
    • Aplasia
      • extracortical axial
    • Farber's disease or syndrome
    • Histiocytosis
      • lipid, lipoid
        • essential
    • Lipidosis
      • sulfatide
    • Lipoid
      • histiocytosis
        • essential
    • Myeloleukodystrophy
    • Sphingolipidosis
      • specified NEC

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NVS006
Other nervous system disorders (often hereditary or degenerative)
Default principal diagnosis: inpatient No · outpatient No
CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Waardenburg Syndrome

    rare, autosomal dominant disease with variable penetrance and several known clinical types. characteristics may include depigmentation of the hair and skin, congenital deafness, heterochromia iridis, medial eyebrow hyperplasia, hypertrophy of the nasal root, and especially dystopia canthorum. the underlying cause may be defective development of the neural crest (neurocristopathy). waardenburg's syndrome may be closely related to piebaldism. klein-waardenburg syndrome refers to a disorder that also includes upper limb abnormalities.
  • Other Sphingolipidosis|Other sphingolipidosis

    evidence of other sphingolipidosis not specified elsewhere.
  • Sphingolipidosis

    an inherited metabolic disorder that affects the metabolism of the spinhgolipids. representative examples include gaucher disease, tay-sachs disease, and niemann-pick disease.
  • Adrenoleukodystrophy|Schilder Disease

    a rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. it leads to progressive neurologic disorders, adrenal insufficiency and death.
  • Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia|ALSP|HDLS|Hereditary Diffuse Leukoencephalopathy with Spheroids|POLD|Pigmentary Orthochromatic Leukodystrophy

    a rapidly progressive neurodegenerative disorder, caused by mutations in the colony-stimulating factor 1 receptor (csf1r) gene, that presents in adulthood with a variety of neuropsychiatric and motor disturbances. hallmark features include diffuse myelin loss and axonal destruction, neuroaxonal spheroids, and pigmented macrophages and other glia.
  • ARSA wt Allele|Arylsulfatase A wt Allele|MLD|Metachromatic Leucodystrophy Gene|Metachromatic Leukodystrophy Gene

    human arsa wild-type allele is located in the vicinity of 22q13.33 and is approximately 3 kb in length. this allele, which encodes arylsulfatase a protein, plays a role in the catabolism of cerebroside sulfate. mutation of the gene is associated with leukodystrophy metachromatic.
  • ATP-Binding Cassette Sub-Family D Member 1|ABCD1|ALDP|Adrenoleukodystrophy Protein|EC 7.6.2.4

    atp-binding cassette sub-family d member (745 aa, ~83 kda) is encoded by the human abcd1 gene. this protein plays a role in the peroxisomal import of fatty acids and fatty acyl-coenzyme a (acylcoa) esters.
  • Canine Globoid Cell Leukodystrophy

    globoid cell leukodystrophy that occurs in a dog.
  • Cerebral Adrenoleukodystrophy|CALD

    a subtype of adrenoleukodystrophy (ald) occurring in approximately 40 percent of boys with ald, primarily affecting the cerebrum, resulting in rapidly declining neurocognitive function and in most patients, premature death.
  • Hypomyelinating Leukodystrophy-6|HABC|HLD6|Hypomyelination with Atrophy of Basal Ganglia and Cerebellum

    a genetic disorder of infancy or early childhood caused by mutation(s) in the tubb4a gene, encoding the tubulin beta-4a chain. it is characterized by hypomyelination or atrophy of the cerebellum and or putamen leading to delayed motor development, gait instability, and extrapyramidal movement disorders.
  • Hypomyelinating Leukodystrophy-8|4H Syndrome|HLD8|Hypomyelination-Hypogonadotropic Hypogonadism-Hypodontia Syndrome

    an autosomal recessive condition caused by mutation(s) in the polr3b gene, encoding dna-directed rna polymerase iii subunit rpc2. it is characterized by early onset cerebellar ataxia and mild intellectual disability. diffuse cerebral hypomyelination and cerebellar atrophy are apparent on mri. hypogonadotropic hypogonadism and hypodontia are also features of this condition.
  • Krabbe Disease|Galactosylceramide Beta-Galactosidase Deficiency|Galactosylceramide Lipidosis|Globoid Cell Leukodystrophy|Krabbe disease

    a rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. it is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.
  • Leukodystrophy

    a group of rare genetic neurodegenerative disorders that affect infants and children. these disorders are characterized by metabolic abnormalities in the development of the myelin sheaths in the white matter. clinical signs and symptoms include developmental delays, mental retardation, dementia, seizures, loss of motor skills, and muscle weakness. representative examples include metachromatic leukodystrophy, krabbe disease, canavan disease, and alexander disease.
  • Metachromatic Leukodystrophy|Metachromatic leukodystrophy

    an autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. it is caused by a deficiency of the enzyme arylsulfatase a. there are three forms of this disease: late infantile, juvenile, and adult. in the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. in the juvenile form symptoms include gait disturbances, mental deterioration and seizures. the adult form is characterized by psychotic symptoms and dementia.
  • Neonatal Adrenoleukodystrophy

    a rare metabolic disorder that affects neonates. it is characterized by damage of the white matter in the brain and degeneration of the adrenal glands. it manifests with hyperactivity, paralysis, muscular weakness, crossed eyes, hearing loss, seizures, and coma.
  • PSAP wt Allele|GLBA|PARK24|PSAPD|Prosaposin wt Allele|SAP1|SAP2|Variant Gaucher Disease and Variant Metachromatic Leukodystrophy Gene

    human psap wild-type allele is located within 10q21-q22 and is approximately 35 kb in length. this allele, which encodes prosaposin protein, plays a role in the positive regulation of lipid hydrolysis. mutation of the gene is associated with combined saposin deficiency, leukodystrophy metachromatic due to saposin-b deficiency, gaucher disease, atypical, due to saposin c deficiency, krabbe disease, atypical, due to saposin a deficiency and tay-sachs disease.
  • Hypomyelinating Leukodystrophy-22|HLD22

    an autosomal dominant condition caused by mutation(s) in the cldn11 gene, encoding claudin-11. it is characterized by global developmental delay, mild impaired intellectual development, limited ability to walk, and hypomyelinating leukodystrophy on mri.
  • Hypomyelinating Leukodystrophy-18|HLD18

    an autosomal recessive condition caused by mutation(s) in the degs1 gene, encoding sphingolipid delta(4)-desaturase des1. it is characterized by the onset of global developmental delay usually in early infancy. affected individuals may also have poor psychomotor development, poor or absent speech, dystonia, and spasticity.
  • Hypomyelinating Leukodystrophy-7|HLD7

    an autosomal recessive condition caused by mutation(s) in the polr3a gene, encoding dna-directed rna polymerase iii subunit rpc1. it is characterized by neurological, dental, ophthalmological, and endocrine alterations, including cognitive impairment, ataxia, hypogonadotropic hypogonadism, and eye abnormalities.

Patient EducationClinical

Genetic Brain Disorders

A genetic brain disorder is caused by a variation or a mutation in a gene. A variation is a different form of a gene. A mutation is a change in a gene. Genetic brain disorders affect the development and function of the brain.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E75.29 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
330.0 Leukodystrophy
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About E75.29Overview

Is E75.29 (Other sphingolipidosis) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report other sphingolipidosis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What is the ICD-9 equivalent of E75.29?

Under the General Equivalence Mappings, other sphingolipidosis converts to ICD-9-CM 330.0 (leukodystrophy). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.